J&J - International Biopharmaceutical Industry

news

FDA places stricter limits on J&J’s COVID-19 vaccine after review of rare side effect

Dive Brief: The Food and Drug Administration has determined that the risk of a rare, but serious, clotting syndrome tied to Johnson & Johnson’s COVID-19 vaccin...

9 May 2022 news COVID-19 | FDA

Continue Reading →

news

J&J cuts COVID vaccine sales forecasts, citing high supplies and lagging demand

Dive Brief: Johnson & Johnson is lowering its forecast for COVID-19 vaccine sales, announcing Tuesday it will has suspended its guidance of $3 billion to $3.5 ...

25 April 2022 news billion | COVID

Continue Reading →

news

J&J to explore RNA reprogramming with Remix research deal

Dive Brief: Johnson & Johnson is partnering with Remix Therapeutics to develop drugs that are meant to reprogram how RNA is processed, becoming the latest big ...

18 February 2022 news drugmakers | J&J

Continue Reading →

news

FDA extends review of J&J, Legend’s cell therapy for multiple myeloma

Abecma and cilta cel are part of an emerging class of multiple myeloma treatments that target a protein called BCMA, which is found on cancer cells. GlaxoSmithKline w...

8 November 2021 news Abecma | cell therapy

Continue Reading →

news

J&J foresees end to not-for-profit sales of coronavirus vaccine

J&J has recorded far fewer sales of its coronavirus vaccine than competitors Pfizer and Moderna, partly due to its not-for-profit pricing but also to a series of ...

22 October 2021 news coronavirus vaccine | J&J

Continue Reading →

news

J&J asks FDA to clear booster dose of its coronavirus vaccine

For the past several months, one of the many questions hanging over the booster debate has ben what do with people who got J&J's shot. The company's application, ...

8 October 2021 news Centers of Disease Control and Prevention | coronavirus vaccine

Continue Reading →

news

After coronavirus success, J&J hits setback with HIV vaccine

Before J&J become one of three companies that earned Food and Drug Administration approval for a coronavirus vaccine, the pharma was already a leader in vaccine d...

3 September 2021 news coronavirus | drugmaker

Continue Reading →

news

With new results, J&J’s $1B gamble on a targeted inflammation drug faces long odds

Izencitinib is a JAK inhibitor, a type of drug that blocks an enzyme involved in inflammation. The drug class is well-established, having already produced multiple ap...

27 August 2021 news autoimmune diseases | enzyme

Continue Reading →

news

J&J’s Janssen to Acquire BeneVir for $1 Billion

Janssen Biotech, part of Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson (J&J), announced on May 2, 2018 that it has entered into a defini...

11 May 2018 news 1Billion | Aquisition

Continue Reading →

Current Edition

Upcoming Events

Advertisement

FDA places stricter limits on J&J’s COVID-19 vaccine after review of rare side effect

J&J cuts COVID vaccine sales forecasts, citing high supplies and lagging demand

J&J to explore RNA reprogramming with Remix research deal

FDA extends review of J&J, Legend’s cell therapy for multiple myeloma

J&J foresees end to not-for-profit sales of coronavirus vaccine

J&J asks FDA to clear booster dose of its coronavirus vaccine

After coronavirus success, J&J hits setback with HIV vaccine

With new results, J&J’s $1B gamble on a targeted inflammation drug faces long odds

J&J’s Janssen to Acquire BeneVir for $1 Billion

International Biopharmaceutical Industry